Prostate cancer is the second most common tumor in men worldwide, accounting for 14% of all new malignancies and the sixth leading cause of tumor death, accounting for 6% of tumor deaths in men. Prostate cancer is an androgen-dependent disease in which androgens stimulate the growth and survival of normal prostate cells or tumor cells, and inhibit apoptosis. Many patients have no obvious symptoms in the early stages, and thus prostate cancer patients are diagnosed at a relatively advanced stage. Studies have shown that in patients with non-metastatic desmoplastic resistant prostate cancer (CRPC stage M0), further detection reveals metastases in 32%-37% of the patients, as the commonly used imaging methods (CT and bone scan) are highly likely to miss systemic micrometastases. Thus, early diagnosis and precise treatment are especially important for prostate cancer patients. Although prostate cancer generally progresses slowly and patients in the early stages can expect to survive for about 10 years, a retrospective study found that the median survival of patients with natural course mCRPC who did not receive any prolonged survival therapy was only 12.3 months. mCRPC patients have a poor prognosis with an expected survival time of 19 months. In progressive prostate cancer, the goals of treatment for physicians and patients should be the same: to control (mitigate, cure) the disease and to prevent (delay) disease progression. Most patients with prostate cancer are not effective with endocrine therapy after 18-24 months of endocrine therapy. Traditional endocrine therapy cannot meet patients’ treatment needs, so how do we choose? 2015 St. Gallen Consensus recommended abiraterone for first-line mCRPC patients, and the new endocrine therapy drug Zecor (abiraterone acetate tablets) in combination with prednisone for mCRPC can bring both survival and quality-of-life benefits and breakthrough patients’ survival dilemma. 2016 EAU trial of 302 (chemotherapy-naïve patients) conducted a stratified analysis and concluded that the median survival of 53.6 months was achieved for patients with less severe chemotherapy-naïve mCRPC (pain score 0-1, PSA <80ng/ml, Gleason score <8) treated with abiraterone + prednisone. The currently approved domestic marketed abiraterone is Zecor from Xi'an Janssen Pharmaceutical Co., Ltd. which, in combination with prednisone, treats patients with metastatic desmoresistant prostate cancer before and after chemotherapy. in January 2016, the "Zecor Life Assistance Program", initiated by the Chinese Primary Health Care Foundation with assistance drugs from Xi'an Janssen Pharmaceutical Co. ", ensures that prostate cancer patients in mainland China can receive standardized treatment, improve access to treatment, reduce family burden, improve quality of life and prolong life.